Search

Your search keyword '"Salwender, Hans"' showing total 18 results

Search Constraints

Start Over You searched for: Author "Salwender, Hans" Remove constraint Author: "Salwender, Hans" Publisher elsevier bv Remove constraint Publisher: elsevier bv
18 results on '"Salwender, Hans"'

Search Results

1. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial

2. OA-43 Analysis of sustained MRD-negativity and progression-free survival of Isa-KRd in high-risk newly diagnosed multiple myeloma – additional data from planned interim analysis of the GMMG-CONCEPT trial

3. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

4. P-177: Predictive factors for severe infections and early death during novel agent-based induction therapy in newly diagnosed, transplant-eligible myeloma: a multicohort analysis from phase III trials

5. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

6. Depth of Response to Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (Isa-KRd) in Front-Line Treatment of High-Risk Multiple Myeloma: Interim Analysis of the GMMG-CONCEPT Trial

7. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

8. Normalization of serum free light chains during therapy in the MM5 trial predicts prolonged progression free survival and overall survival

9. Comparison of bortezomib versus lenalidomide maintenance therapy in newly-diagnosed, transplant-eligible multiple myeloma: Results from the phase III GMMG-HD4 and -MM5 trials

10. A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

11. Impact of cytogenetics at relapse on prognosis and benefit from salvage autologous stem cell transplantation in the GMMG phase III trial ReLApsE

12. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

14. Survival of elderly patients with multiple myeloma—Effect of upfront autologous stem cell transplantation

15. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Catalog

Books, media, physical & digital resources